MA-VERISTAT
11.1.2022 16:37:05 CET | Business Wire | Press release
Veristat, a scientific-minded global clinical research organization (CRO), announced today that the Company supported clients in preparing marketing applications for 12% of the 2021 U.S. Food and Drug Administration (FDA) novel drug approvals. This surpasses the number of approvals supported in 2020. In 2021, the FDA approved 50 novel drugs, defined as New Molecular Entities (NMEs) .
Veristat’s bold thinking, focus, and extensive experience supporting complex drug development in rare and ultra-rare diseases significantly impacted these transformational medicines designed for patients with few or no treatment options. The work of Veristat’s innovative regulatory, statistical, and medical writing experts was vital in preparing six of these NME New Drug Applications (NDAs) and Biologics License Applications (BLAs). Veristat also prepared one supplemental New Drug Application (sNDA) for a non-NME that received FDA approval and one Marketing Authorization Application (MAA) that received approval in Europe. All but one of these 2021 approvals are for rare diseases.
“Throughout 2021 and in collaboration with our sponsors, we were able to successfully overcome the many scientific, regulatory, and data challenges that novel therapy research presents. We are grateful for the opportunity to have collaborated with our clients to achieve their goals and to bring novel therapies to patients,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Despite the remarkable advances in recent years in the understanding of rare diseases and in the approval of medicines to treat them, many unmet needs of patients remain. Our work continues with efforts such as the expansion of decentralized clinical trials that bring clinical research closer to the patient’s home.”
Since the Company’s founding 27 years ago, Veristat has collaborated with hundreds of biopharmaceutical clients around the globe to prepare more than 140 marketing applications. More than 65% of these marketing applications for rare and ultra-rare diseases. While a large majority of these engagements were with the FDA, the Company also holds an impressive track record with Health Canada and the European Medicines Agency (EMA). And with the recent acquisition of European regulatory consultancy agency Drug Development and Regulation (DDR) — and with it Dr. Xavier Luria, former Head of Safety and Efficacy of Medicines at the EMA— Veristat can provide clients with a deep understanding of the EMA and other key regulators.
“Advancing complex therapies for challenging diseases is what motivates us every day,” said John Balser, Ph.D., President & Chief Statistical Officer at Veristat. “It is gratifying to know that our scientific-minded teams were instrumental in helping clients prepare these marketing applications for therapies that received approval, thereby helping to improve the lives of patients and their families. A large part of our success, and what distinguishes Veristat, is the ability of our multi-disciplinary project teams to draw the appropriate connections amongst the fundamental constructs of the science, the practical and operational requirements of the clinical program, and the regulatory pathway, that combined provide the evidentiary basis for product approval. In 2022, Veristat will build upon our world-class biometrics, clinical, and regulatory capabilities to successfully tackle challenging diseases and meet the goals of our clients.”
About Veristat
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 27 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. Every day, we apply this knowledge base to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005478/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
teamLab Biovortex Kyoto to Open 'Teahouse in a Sea of Light' for Savoring Tea. On View from Friday, November 20. Artworks Including Tea in Spontaneous Order on View20.11.2026 07:00:00 CET | Press release
teamLab Biovortex Kyoto opens ‘Teahouse in a Sea of Light’ on Friday, November 20, 2026, where visitors can savor tea within the Sea of Solidified Light. Artworks exhibited in the teahouse, including Tea in Spontaneous Order, are now unveiled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117922442/en/ Aged Coffee Tonic, Tea in Spontaneous Order, 2021- ©︎ teamLab *Shot in real space. No AI or CGI. *No Artificial Colors Teahouse in a Sea of Light A space for savoring tea within a sea of light. When a cup of tea is made, the artwork is born. The tea interacts with nearby tea and the sea of light, creating a time structure throughout the entire space of the artwork. Visitors drink part of this formed order itself. Coinciding with the opening of ‘Teahouse in a Sea of Light,’ Pocket Garden of Eternal Existence is newly unveiled at the museum's entrance gate. teamLab Biovortex Kyoto teamLab Biovortex Kyoto is teamLab's largest
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release
Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release
Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release
Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
